Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.
Performance of psychedelic public companies this past week.
Numinus Wellness ($NUMI | $NUMIF) received Health Canada Special Access Program approval to provide psilocybin-assisted therapy to a patient with treatment-resistant depression. This is Numinus' first psilocybin-assisted therapy treatment outside of ongoing clinical trials. Press Release
MindMed ($MMED | $MNMD) provided positive safety and tolerability results from their Phase I trial focused on their non-hallucinogenic proprietary ibogaine analogue as a potential treatment for opioid withdrawal. Press Release
PsyBio Therapeutics ($PSYB | $PSYBF) achieved a commercially scalable purification method for one of their second generation compounds. The manufacturing process is expected to further expand PsyBio's portfolio of compounds that can be more readily and rapidly developed than competitive methods. Press Release
Awakn Life Sciences ($AWKN | $AWKNF) completed the world's first ketamine treatment study for behavioral addictions, including gambling disorder, internet gaming disorder, binge eating disorder and compulsive sexual behavior. Press Release
HAVN Life ($HAVN | $HAVLF) partnered with TheraPsil and will participate in their Project Solace as a Health Canada-approved licensed dealer to supply GMP-quality psilocybin for legal and therapeutic use via the Special Access Program. Press Release
Filament Health ($FH | $FLHLF) has been issued a second patent for the extraction and standardization of natural psilocybin. The patent describes technology for transforming variable psychedelic raw materials into pharmaceutical-grade drug candidates. Press Release
Optimi Health ($OPTI | $OPTHF) acquired a diverse catalog of psilocybin and functional mushroom strains used for cultivation in their, EU-GMP compliant facility in British Columbia. The acquisition includes 24 psychedelic and nine functional strains, giving it one of the largest genetic banks in the sector. Press Release
Clearmind Medicine ($CMND | $CMNDF) announced positive results from their proprietary psychedelic molecule, MEAI, as a potential treatment for alcohol addiction. Pre-clinical trial demonstrated safety and efficacy in reducing alcohol consumption. Press Release
Braxia Scientific ($BRAX | $BRAXF) received Health Canada Special Access Program approval to provide psilocybin-assisted psychotherapy for an Ontario patient with Major Depressive Disorder through their wholly owned subsidiary Canadian Rapid Treatment Centre of Excellence. Press Release
Albert Labs International ($ABRT) has been granted a Health Canada License for their research and production facility. This approval allows the legal possession, production, assembly, sale, and delivery of psilocybin and other psychoactive controlled substances. Press Release
Psychedelic Finance: Interview With Aaron Bartlone Of Cybin
BNN Bloomberg: Investors Are Talking About Psychedelics
Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.